Market News Latest

The dynamics of the Autism Spectrum Disorders market is anticipated to change in the upcoming years owing to the improvement in the diagnosis methodologies along with the launch of emerging therapies

 Breaking News
  • No posts were found

The dynamics of the Autism Spectrum Disorders market is anticipated to change in the upcoming years owing to the improvement in the diagnosis methodologies along with the launch of emerging therapies

September 22
13:58 2021
The dynamics of the Autism Spectrum Disorders market is anticipated to change in the upcoming years owing to the improvement in the diagnosis methodologies along with the launch of emerging therapies
Autism Spectrum Disorders Market
The recent technical improvements in diagnosis, therapy, awareness, funding, and improving the functioning of a child with ASD’s family provide optimism for future ASD treatment.

DelveInsight’s Autism Spectrum Disorders market report provide information on existing clinical strategies, new drugs, available therapies, epidemiology,  Autism Spectrum Disorders market share of individual treatments, and current and forecasted Autism Spectrum Disorders market trends in the 7MM (the US, EU5 (the Uk, France, Germany, Italy, and Spain), and Japan.

Some of the Key Highlights from the Autism Spectrum Disorders Market Report

  • As per Centers for Disease Control and Prevention (CDC) estimate, approximately one in every 68 children in the United States has Autism.

  • According to Manabu Saito’s (2020) study in Japan, the adjusted Autism Spectrum Disorders prevalence was 3.22 percent.

  • Various pharmaceutical companies such as Curemark, Otsuka Pharmaceutical, Janssen  Pharmaceutical, GW Research, Zynerba, Roche, and others are developing therapies to treat Autism Spectrum Disorders.

  • Key ASD pipeline therapies include CM-AT, Brexpiprazole, JNJ-42165279, GWP42006, Zygel, RO 7017773, and others.

  • RO 7017773 (Hoffmann-La Roche) is a small molecule that is a highly selective positive allosteric modulator of the GABAA 5 receptor, which is expressed in key brain regions for autism spectrum disorder.

  • GWP42006 (GW Research) is a non-psychoactive cannabinoid cannabidivarin (CBDV) extracted from the cannabis plant. The company has been testing GWP42006 in both general and syndromic pre-clinical models of ASD, with promising results on cognitive and social endpoints, as well as repetitive behavior.

For further information on the disease, request for the sample @ Autism Spectrum Disorders Market Analysis and Forecast

Autism Spectrum Disorders Overview

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by difficulties in social communication and interaction and restricted and repetitive patterns in behaviors, interests, and activities By definition, the symptoms appear early in development and interfere with daily functioning.

Autism Spectrum Disorders Epidemiology Segmentation

The Autism Spectrum Disorders report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into: 

  • Autism Spectrum Disorders Total Prevalent Pool

  • Autism Spectrum Disorders Gender-Specific Prevalent Pool

  • Autism Spectrum Disorders Age-Specific Prevalent Pool

  • Autism Spectrum Disorders Total Diagnosed Cases

Autism Spectrum Disorders Therapeutics Market

There are numerous ASD treatment options available. The most effective ASD treatments used currently are Applied Behavioral Analysis (ABA), Occupational Therapy, Speech Therapy, Physical Therapy, and Pharmacological Therapy. Some FDA-approved drugs such as Risperidone, Aripiprazole, and Slenyto are also used to treat Autism Spectrum Disorders.

Autism Spectrum Disorders Market Outlook

The technological advancements achieved in the recent decade in terms of diagnosis, therapy, awareness, funding, and enhancing the functioning of a kid with ASD’s family provide hope for future ASD treatment. 

Furthermore, the introduction of CM-AT, Brexpiprazole, JNJ-42165279, GWP42006, and others are expected to give the Autism Spectrum Disorders market a significant boost in the forecast period 2021-30 in the 7MM.

Get more information about the emerging treatment options @ Autism Spectrum Disorders Market Size

Autism Spectrum Disorders Pipeline Therapies and Key Companies

  • CM-AT: Curemark

  • Brexpiprazole: Otsuka Pharmaceutical

  • JNJ-42165279: Janssen Pharmaceutical

  • GWP42006: GW Research

  • Zygel: Zynerba

  • RO 7017773: Roche

Autism Spectrum Disorders Market Drivers

  • Increasing R&D

  • Rising ASD Prevalence

  • Government Initiatives

Autism Spectrum Disorders Market Barriers

  • Unknown etiology & pathophysiology

  • Lack of approved Therapies

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Autism Spectrum Disorders Key Companies: Curemark, Otsuka Pharmaceutical, Janssen  Pharmaceutical, GW Research, Zynerba, Roche, among others. 

Autism Spectrum Disorders Key Pipeline Therapies: CM-AT, Brexpiprazole, JNJ-42165279, GWP42006, Zygel, RO 7017773, and others.

Autism Spectrum Disorders Segmentation: By Geography, By Autism Spectrum Disorders therapies

Analysis: Comparative and conjoint analysis of Autism Spectrum Disorders emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Report Introduction

2.

Autism Spectrum Disorders (ASD): Market Overview at a Glance

3.

Executive Summary

4.

Disease Background and Overview: Autism Spectrum Disorders (ASD) 

5.

Epidemiology and Patient Population 

6.

Assumptions and Rationale

7.

Autism Spectrum Disorders (ASD): Country-wise Epidemiology

8.

Organizations

9.

Patient Journey

10.

Case Report

11.

Autism Spectrum Disorders Marketed Products

12.

Autism Spectrum Disorders Emerging Therapies

13.

Key Cross Competitors 

14.

Autism Spectrum Disorders (ASD): Market Size

15.

Autism Spectrum Disorders Unmet Needs

16.

Autism Spectrum Disorders Market Drivers

17.

Autism Spectrum Disorders Market Barriers

18.

KOL

19.

Report Methodology

20.

Sources Used

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Autism Epidemiology Forecast

DelveInsight’s ‘Autism – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Autism epidemiology in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/